Mereo BioPharma
MREO
61 hedge funds and large institutions have $46.2M invested in Mereo BioPharma in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 8 closing their positions.
7% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 14
7% more call options, than puts
Call options by funds: $93K | Put options by funds: $87K
1.03% less ownership
Funds ownership: 10.88% → 9.85% (-1%)
3% less funds holding
Funds holding: 63 → 61 (-2)
7% less capital invested
Capital invested by funds: $49.4M → $46.2M (-$3.27M)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAM
Monaco Asset Management
Monaco
|
+$1.53M |
| 2 |
Goldman Sachs
New York
|
+$1.3M |
| 3 |
E
Ergoteles
New York
|
+$109K |
| 4 |
JP Morgan Chase
New York
|
+$109K |
| 5 |
Barclays
London,
United Kingdom
|
+$104K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.46M |
| 2 |
CC
Clearline Capital
New York
|
-$1.56M |
| 3 |
BlackRock
New York
|
-$565K |
| 4 |
Morgan Stanley
New York
|
-$99.9K |
| 5 |
CHAM
Clear Harbor Asset Management
Stamford,
Connecticut
|
-$50.1K |
MREO Hedge Fund Activity: Q4 2022 in Review
61 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q4 2022, worth a combined $46.2M — down 6.6% from $49.4M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of MREO and 6 opened new positions — a net loss of 2 holders — while 14 trimmed existing stakes and 15 added.
The largest buyer was Monaco Asset Management, adding an estimated $1.53M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $8.46M sold.
- 61 institutional investors held Mereo BioPharma (MREO) as of Q4 2022, down from 63 in Q3 2022.
- Funds reported $46.2M of Mereo BioPharma stock for Q4 2022, down 6.6% quarter-over-quarter.
- 6 funds opened new Mereo BioPharma positions in Q4 2022 and 8 closed out, a net change of -2 holders.
- The largest Mereo BioPharma buyer in Q4 2022 was Monaco Asset Management, an estimated $1.53M added.
- The largest Mereo BioPharma seller in Q4 2022 was Point72 Asset Management, an estimated $8.46M sold.
Based on aggregated 13F filings for Q4 2022.